Fourth World Antibody-Drug Conjugate Summit

Antibody-maytansinoid conjugates: A new strategy for the treatment of cancer

(2015) J.M. Lambert   DRUGS OF THE FUTURE

Abstract 1781: Lorvotuzumab mertansine (IMGN901) in combination with standard-of-care paclitaxel/carboplatin therapy is highly active in a preclinical xenograft model of ovarian cancer

(2014) Kathleen R. Whiteman et al.   CANCER RESEARCH

Abstract 1760: Preclinical evaluation of IMGN853, an anti-FOLR1 antibody-maytansinoid conjugate, as a potential therapeutic for ovarian cancer

(2014) Kathleen R. Whiteman et al.   CANCER RESEARCH

Abstract 2830: Antibody and linker selection for the anti-CD37 antibody-maytansinoid conjugate IMGN529 for the treatment of B-cell malignancies

(2012) Peter U. Park et al.   CANCER RESEARCH

Abstract 4565: IMGN529: A therapeutic maytansinoid conjugate of an anti-CD37 antibody with multiple mechanisms of action for B-cell lymphoma and leukemia

(2012) Jutta Deckert et al.   CANCER RESEARCH

Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy

(2012) Olga Ab et al.   CANCER RESEARCH

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody–drug conjugates: Basic concepts, examples and future perspectives

(2012) Giulio Casi et al.   JOURNAL OF CONTROLLED RELEASE

7th Annual European Antibody Congress 2011

(2012) Alexey A. Lugovskoy et al.   mAbs

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Pharmacokinetic Considerations for Antibody Drug Conjugates

(2012) Kedan Lin et al.   PHARMACEUTICAL RESEARCH

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

(2011) C. Andrew Boswell et al.   BIOCONJUGATE CHEMISTRY

A novel pathway for maytansinoid release from thioether linked antibody–drug conjugates (ADCs) under oxidative conditions

(2011) Nathan Fishkin et al.   CHEMICAL COMMUNICATIONS

SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies

(2011) V. Blanc et al.   CLINICAL CANCER RESEARCH

Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer

(2011) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Antibody Conjugate Therapeutics: Challenges and Potential

(2011) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976)

(2011) S. Hurvitz et al.   EUROPEAN JOURNAL OF CANCER

Investigational antibody drug conjugates for solid tumors

(2011) Puja Sapra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

(2011) Simona Lapusan et al.   INVESTIGATIONAL NEW DRUGS

Bispecific antibodies and ADCs

(2011) Janice M. Reichert   mAbs

World Antibody Drug Conjugate Summit Europe

(2011) Alain Beck et al.   mAbs

The amazing, multipurpose antibody

(2011) Alain Beck et al.   mAbs

Bispecific digoxigenin-binding antibodies for targeted payload delivery

(2011) S. Metz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate

(2010) N. M. Okeley et al.   CLINICAL CANCER RESEARCH

226 High in vivo anti-tumor activity of the immunoconjugate BT-062 against CD138 positive solid tumors

(2010) C. Zuber et al.   EJC SUPPLEMENTS

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Novel photosensitisers derived from pyropheophorbide-a: uptake by cells and photodynamic efficiency in vitro

(2010) Ioanna Stamati et al.   PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo

(2009) H. Ikeda et al.   CLINICAL CANCER RESEARCH

Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin

(2009) Jeannick Cizeau et al.   JOURNAL OF IMMUNOTHERAPY

Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates

(2008) Stephen C. Alley et al.   BIOCONJUGATE CHEMISTRY

Antibody-Drug Conjugates for Cancer Therapy

(2008) Paul J. Carter et al.   CANCER JOURNAL

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma

(2008) Herbert Riechelmann et al.   ORAL ONCOLOGY